Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-14
2008-11-11
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S233500, C544S133000
Reexamination Certificate
active
07449461
ABSTRACT:
The present invention relates to compounds of the general formulawhereinR1is cycloalkyl, substituted by OR or is 2-(7-oxa-bicyclo[2.2.1]hept-1-yl)-ethyl;R is hydrogen, lower alkyl or C(O)-lower alkyl;X is —CHR′—; andR′ is hydrogen or lower alkyl;and pharmaceutically acceptable acid addition salts, optically pure enantiomeres, racemates or diastereomeric mixtures thereof for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse, or for use as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents for coronary artery disease and heart failure.
REFERENCES:
patent: 6284759 (2001-09-01), He
patent: 6521754 (2003-02-01), Alanine et al.
patent: 2003/0153566 (2003-08-01), Flohr et al.
patent: 2004/0235842 (2004-11-01), Flohr et al.
patent: 2004/0242576 (2004-12-01), Flohr et al.
patent: WO 01/97786 (2001-12-01), None
patent: WO 03/043634 (2003-05-01), None
patent: WO 03/043636 (2003-05-01), None
patent: WO 03/045386 (2003-06-01), None
patent: WO 03/049741 (2003-06-01), None
Poulsen, et al., Bioorganic and Medicinal Chemistry 6(6) 619-641, 1998 Adenosine receptors: New opportunities for future drugs.
Müller et al., Bioorganic and Medicinal Chemistry 6(6) 707-719, 1998 8-(Sulfostyryl)xanthines: water-soluble A2A-selective adenosine receptor antagonists.
Kim et al., Journal of Medicinal Chemistry 41(15) 2835-2845, 1998 Derivatives of the Triazoloquinazoline Adenosine Antagonist (CGS 15943) Having High Potency at the Human A2Band A3Receptor Subtypes.
Li et al., Journal of Medicinal Chemistry 41(17) 3186-3201, 1998 Structure-Activity Relationships and Molecular Modeling of 3,5-Diacyl-2,4-dialkylpyridine Derivatives as Selective A3Adenosine Receptor Antagonists.
Baraldi, et al., Journal of Medicinal Chemistry 41(12) 2126-2133, 1998 Design, Synthesis, and Biological Evaluation of a Second Generation of Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as Potent and Selective A2AAdenosine Receptor Antagonists.
Li et al., Journal of Medicinal Chemistry 42(4) 706-721, 1999 Synthesis, CoMFA Analysis, and Receptor Docking of 3,5-Diacyl-2,4-Dialkylpyridine Derivatives as Selective A3Adenosine Receptor Antagonists.
Baraldi et al., Journal of Medicinal Chemistry 39(5) 1164-1171, 1996 Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives: Potent and Selective A2AAdenosine Antagonists.
Colotta et al., Arch. Pharm. Pharm. Med. Chem. 332(2) 39-41, 1999 4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo [4,3-alpha]-quinoxalin-1-one: a new A2Aadenosine receptor antagonist with high selectivity versus A1receptors.
Auchampach, et al., American Journal of Physiology 276(3 Pt 2) H1113-H1116, 1999, Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges.
Haas et al., Naunyn Schmiedeberg's Archives of Pharmacology 362(4-5) 375-381, 2000, Functions of neuronal adenosine receptors.
Dionisotti et al., British Journal of Pharmacology 121(3) 353-360, 1997 Characterization of human A2Aadenosine receptors with the antagonist radioligand [3H]-SCH 58261.
Boutagy et al., Chemical Reviews 74(1) 87-99, 1974 Olefin synthesis with organic phosphonate carbanions.
Flohr Alexander
Riemer Claus
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
Shiao Rei-tsang
LandOfFree
Benzathiazol-acetamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzathiazol-acetamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzathiazol-acetamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4037100